Stockscreener 앱 받기
33.67
1.81%
0.60
시간 외 거래:
33.67
전일 마감가:
$33.07
열려 있는:
$33.515
하루 거래량:
2.07M
Relative Volume:
0.97
시가총액:
$5.75B
수익:
-
순이익/손실:
$-354.30M
주가수익비율:
-13.34
EPS:
-2.5234
순현금흐름:
$-286.27M
1주 성능:
+7.30%
1개월 성능:
+3.03%
6개월 성능:
-14.65%
1년 성능:
+341.86%
1일 변동 폭
$32.95
$34.00
1주일 범위
$31.09
$34.00
52주 변동 폭
$6.92
$43.73
코젠트 바이오사이언시스 Stock (COGT) Company Profile
명칭
Cogent Biosciences Inc
전화
617-945-5576
주소
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
33.67 | 5.67B | 0 | -354.30M | -286.27M | -2.5234 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
코젠트 바이오사이언시스 Stock (COGT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2025-11-10 | 업그레이드 | Stifel | Hold → Buy |
| 2025-11-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2025-10-16 | 개시 | Stifel | Hold |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-11 | 다운그레이드 | Needham | Buy → Hold |
| 2024-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | 개시 | Citigroup | Buy |
| 2023-12-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-12-08 | 개시 | JP Morgan | Overweight |
| 2023-04-28 | 개시 | Robert W. Baird | Outperform |
| 2023-03-27 | 재개 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-06-28 | 개시 | Guggenheim | Buy |
| 2021-10-11 | 개시 | H.C. Wainwright | Buy |
| 2021-06-09 | 재개 | Jefferies | Buy |
| 2020-12-23 | 개시 | Piper Sandler | Overweight |
| 2020-10-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
코젠트 바이오사이언시스 주식(COGT)의 최신 뉴스
Stifel reiterates Cogent stock Buy rating after trial data - Investing.com UK
Stifel reiterates Cogent stock Buy rating after trial data By Investing.com - Investing.com India
Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage (NASDAQ:COGT) - Seeking Alpha
Cogent Biosciences, Inc. (COGT) Presents at European Hematology Association (EHA) 2026 CongressSlideshow - Seeking Alpha
Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial - Moomoo
Cogent Biosciences unveils pivotal APEX trial data at EHA 2026 - grafa.com
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association Congress - Investing News Network
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association Congress - Investing News Network
Cogent Gallops on Data Release - Baystreet.ca
Cogent unveils positive preclinical data for JAK2 inhibitor CGT1145 - grafa.com
Experimental JAK2 inhibitor targets mutation in most polycythemia vera cases - Stock Titan
Cogent Biosciences Announces Detailed Data from Apex Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis - marketscreener.com
Director for Cogent Biosciences (NASDAQ: COGT) granted 17,901 stock options - Stock Titan
Cogent Biosciences (COGT) director receives 17,901 stock options at $31.98 strike - Stock Titan
Cogent Biosciences (COGT) director linked to option grant for funds - Stock Titan
Director at Cogent Biosciences (NASDAQ: COGT) receives 17,901 stock options - Stock Titan
Cogent Biosciences (COGT) director Arlene Morris receives grant of 17,901 stock options - Stock Titan
Cogent Biosciences (NASDAQ: COGT) 2026 meeting backs board, auditor and pay - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
How Investors May Respond To Cogent Biosciences (COGT) Priority Review For Bezuclastinib GIST Regimen - Yahoo Finance
Cogent Biosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now? - Insider Monkey
Cogent Biosciences (COGT) Is Down 7.3% After Priority Review Win For Bezuclastinib Combo In GISTHas The Bull Case Changed? - Sahm
COGT News | COGENT BIOSCIENCES INC (NASDAQ:COGT) - ChartMill
Analysts Are Bullish on Top Healthcare Stocks: Agios Pharma (AGIO), Cogent Biosciences (COGT) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Summit Therapeutics (SMMT), Oculis Holding (OCS) and Cogent Biosciences (COGT) - The Globe and Mail
Assessing Cogent Biosciences (COGT) Valuation After PEAK Phase 3 Success And FDA Priority Review - Sahm
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Medline (MDLN) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL), Cogent Biosciences (COGT) and Anteris Technologies Global Corp. (AVR) - The Globe and Mail
COGT Technical Analysis & Stock Price Forecast - Intellectia AI
Stifel reiterates Cogent stock Buy rating on GIST drug data - Investing.com UK
Stifel Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Stifel reiterates Cogent stock Buy rating on GIST drug data By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Cogent stock rating on trial results By Investing.com - Investing.com Australia
Cogent Biosciences Stock Surges 136%. Investors See Promise in Its Cancer Drug. - MSN
UBS Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Cogent Biosciences (COGT) Reveals Promising Phase 3 Trial Results for Bezuclastinib - GuruFocus
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors at 2026 American Society of Clinical Oncology Annual Meeting - Investing News Network
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Cogent Biosciences (COGT) and GlaxoSmithKline (GSK) - The Globe and Mail
Cogent Biosciences presented detailed clinical data from its PEAK Phase III trial at the 2026 American Society of Clinical Oncology Annual Meeting. - Bitget
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of... - markets.businessinsider.com
Cogent Biosciences announces detailed clinical data from peak phase 3 trial with bezuclastinib in combination with sunitinib - marketscreener.com
Cogent Biosciences Announces Detailed Clinical Data From Peak Phase 3 Trial With Bezuclastinib In Combination With Sunitinib - TradingView
Drug combo lets GIST patients go 16.5 months before tumors worsen - Stock Titan
Cogent Biosciences Company Profile & Introduction - Moomoo
Wedbush Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
COGT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
COGT Reiterates by Wedbush -- Price Target Maintained at $55 - GuruFocus
HC Wainwright & Co. Maintains Cogent Biosciences (COGT) Buy Recommendation - MSN
Cogent Biosciences (COGT) Receives FDA Acceptance for New Drug A - GuruFocus
Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference - Sahm
코젠트 바이오사이언시스 (COGT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
코젠트 바이오사이언시스 주식 (COGT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Mar 31 '26 |
Sale |
34.66 |
7,000,000 |
242,620,000 |
5,503,418 |
| Fairmount Funds Management LLC | Director |
Jan 22 '26 |
Sale |
36.40 |
3,500,000 |
127,400,000 |
5,503,418 |
2.60%
0.94%
자본화:
|
볼륨(24시간):